This first case illustrates that patients with advanced serous high-grade ovarian cancer with a strong family history and BRCA1 mutation can have a long-term derived benefit under Olaparib treatment, with good quality of life and prolonged progression-free survival and overall survival, even in the context of poorly tolerated chemotherapy. This evidence concerns the gene BRCA1 and ovarian cancer.